From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Cardiology>
  4. Summary and Comment

Is MDA-Modified LDL a Marker for Acute Coronary Syndromes?

Coronary endothelial injury is associated with platelet adhesion, aggregation synthesis of prostaglandins, and the release of aldehydes that bind to low-density lipoprotein (LDL) to create malondialdehyde (MDA)-modified LDL. Belgian investigators compared MDA-modified LDL, troponin I, and C-reactive protein as markers for stable coronary disease (n=64), unstable angina (n=42), and acute MI (n=62).

Univariate analysis revealed an association of acute coronary syndromes with elevated levels of C-reactive protein, troponin I, and MDA-modified LDL. On multivariate analysis, elevated levels of MDA-modified LDL correlated with unstable coronary syndromes, but troponin I most strongly correlated with acute MI. With cutoff values exceeding the 95th percentile of patients with stable angina, the sensitivity of MDA-modified LDL was 95 percent for unstable angina and 95 percent for acute MI, with a specificity of 95 percent. The combined sensitivity of MDA-modified LDL plus troponin I was 98 percent for unstable angina and 100 percent for acute MI, with a combined specificity of 99 percent. By combining assays, physicians may be able to identify the presence of coronary plaque instability and myocardial cell injury, thus improving the ability to diagnose and stratify patients with acute coronary syndromes.

Comment: This small, interesting study of patients with acute coronary syndromes indicates that biochemical assays may help identify patients with unstable coronary plaques even without myocardial cell injury. (The authors of this paper created the MDA-modified LDL assay.) More studies are needed to verify these results in larger groups of patients at other centers.

— KA Eagle

Published in Journal Watch Cardiology July 16, 1999

Citation(s):

Holvoet P et al. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999 May 12 281 1718-1721.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 1999. Massachusetts Medical Society. All rights reserved.